Key facts
- Allozymes’s last known valuation is $45.4M.
- It has raised $23.3M; the latest was Later Stage VC ($15.0M) in May 2024.
- Notable investors include Plug and Play Tech Center, Transpose Platform Management, SOSV, Entrepreneurs First, Temasek Holdings — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Allozymes
- ·The full record, as it builds
Funding rounds
No funding rounds for Allozymes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Allozymes
Developer of microfluidic technology designed to support the development and testing of enzymes. The company's platform helps employ molecular biology and process engineering to produce proteins and deliver precise proteins in the form of pure enzymes for the target application, enabling clients to accelerate custom enzyme development and develop novel, sustainable natural products.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2019
- Employees
- 31
- Website
- allozymes.com/
- Ownership
- Privately Held (backing)
Allozymes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allozymes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allozymes in its N-PORT filings yet. We sweep new filings monthly.